Aktieanalys

Moberg Pharma Q2’22: On track to Launch - Redeye

Redeye Publicerad: 09 Aug 2022 10:11

Redeye’s comments on the Q2 report that was published earlier this morning. As expected, there were no sales, and the main events during the quarter were the completed issue and the enrollment of patients for the Phase 3 study for MOB-015 in North America. With progress in the registration process, the clinical study, and other preparations for launch in 2023, Moberg Pharma is very much on track. We do not change our fair value range and Base case value of SEK 8 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/850283/moberg-pharma-q222-on-track-to-launch?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!